CTRI/2021/05/033302已完成未知
An open label comparative study to evaluate safety and effectiveness of intraarticularinjection of Autologous Growth Factor Concentrate (AGFC) versusHyaluronic acid (HA) in Knee Osteoarthritis
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Confirmed osteoarthritis of the knee joint on radiological assessment
- •(Grade I, II & III on Kellgren-Lawrence Grading Scale) and
- •2. Visual Analogue Scale (VAS) pain score of 4 or more (on numeric
- •rating scale) since past 2 weeks in spite of taking NSAIDs
排除标准
- •1. Grade IV on Kellgren-Lawrence Grading Scale
- •2. Past surgery or fracture on knee joint
- •3. Knee instability
研究者
相似试验
Unknown
2 期
A Clinical Study to evaluate the Safety and Efficacy of LP011-09 in subjects with Allergic RhinitisCTRI/2012/03/002473aila Pharmaceutical Pvt Ltd40
已完成
4 期
An open label study to evaluate the safety and efficacy of Aclasta (Zoledronic acid) in treatment of patients with Glucocorticoid induced OsteoporosisCTRI/2010/091/000637ovartis Healthcare Pvt Limited60
进行中（未招募）
1 期
A study to evaluate the safety and effect of CFZ533 on patients with Graves’ diseaseGraves' diseaseMedDRA version: 19.0Level: LLTClassification code 10018706Term: Graves' diseaseSystem Organ Class: 100000004860EUCTR2015-005564-41-DEovartis Pharma Services AG15
进行中（未招募）
1 期
An open label extentsion study to evaluate safety, tolerability, and efficacy of 18 weeks of valsartan treatment in children 6 months -5 years old with hypertension.HypertensionEUCTR2006-005473-21-BEovartis Pharma Services AG66
进行中（未招募）
不适用
An open label extentsion study to evaluate safety, tolerability, and efficacy of 18 weeks of valsartan treatment in children 1-5 years old with hypertension.HypertensionEUCTR2006-005473-21-HUovartis Pharma Services AG68